ArticleFrontiers in oncology2025

TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study.

Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.